Examkin

Question

Difficulty: Very hardRheumatology and Immunology

A 28-year-old woman with a known history of systemic lupus erythematosus (SLE) presents to the nephrology clinic with new-onset hypertension, progressive lower extremity edema, and foamy urine. Laboratory evaluation reveals a serum creatinine of 1.7 mg/dL, a serum albumin level of 2.6 g/dL, and a urine protein-to-creatinine ratio of 3.8 g/g. Urinalysis demonstrates dysmorphic red blood cells and red blood cell casts.

Assuming the patient initially follows a standard favorable clinical trajectory but eventually experiences a severe, treatment-resistant flare several years later, arrange the following clinical interventions in the correct chronological sequence of her long-term management.

  1. 1Perform an ultrasound-guided percutaneous renal biopsy to determine the histopathologic class.
  2. 2Initiate aggressive induction therapy with high-dose glucocorticoids combined with mycophenolate mofetil.
  3. 3Document a partial or complete renal response after 3 to 6 months of the intense immunosuppressive regimen.
  4. 4Transition to long-term maintenance therapy utilizing lower-dose mycophenolate mofetil or azathioprine.
  5. 5Escalate therapy to a calcineurin inhibitor or B-cell depleting biologic upon diagnosis of a refractory relapse.

Answer

The correct sequence is: 1) Renal biopsy, 2) Induction therapy, 3) Document response at 3-6 months, 4) Maintenance therapy, 5) Escalation for refractory relapse.
The standard sequence for managing active lupus nephritis requires establishing a histological baseline via biopsy before committing to highly toxic induction therapy. Induction (e.g., high-dose steroids and mycophenolate) aims to rapidly halt inflammation. The efficacy of this phase must be evaluated after 3 to 6 months. Once a response is documented, the patient is safely stepped down to maintenance therapy to minimize long-term toxicity. Finally, if the disease relapses and proves refractory years later, escalation to salvage agents like voclosporin or rituximab is indicated.

Step-by-Step Solution

1
Identify the need for a definitive tissue diagnosis in a patient presenting with signs of active, severe lupus nephritis.
Place the performance of a renal biopsy as the initial step.
Empiric treatment without classifying the specific WHO/ISN histological class is inappropriate, as the class dictates the treatment protocol.
2
Determine the immediate pharmacological management following histological confirmation of proliferative lupus nephritis.
Place the initiation of high-dose induction therapy as the second step.
Rapid, aggressive immunosuppression is required to halt immune-mediated renal damage and induce remission.
3
Establish the timeframe for evaluating the efficacy of the initial intense treatment phase.
Place the documentation of clinical response at 3 to 6 months as the third step.
Induction therapy regimens require several months to achieve maximal clinical effect; premature alteration of therapy should be avoided.
4
Select the appropriate ongoing management strategy once disease remission is achieved.
Place the transition to lower-dose maintenance therapy as the fourth step.
Maintenance therapy uses lower medication doses to sustain remission while reducing the risk of long-term toxicity, such as opportunistic infections.
5
Formulate a plan for a subsequent severe, treatment-resistant disease flare.
Place the escalation to calcineurin inhibitors or biologics as the final step.
Advanced, targeted therapies are reserved for salvage treatment in patients who eventually relapse and become refractory to standard regimens.

Key Concept

The standard management algorithm for proliferative lupus nephritis follows a strict sequence: diagnostic renal biopsy, intense induction therapy, formal assessment of response, transition to less toxic maintenance therapy, and ultimately, targeted escalation for refractory relapses.
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic